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Abstract
The Hippo signaling pathway regulates cellular proliferation and survival, thus exerting profound effects on normal cell 
fate and tumorigenesis. Dysfunction of the Hippo pathway components has been linked with breast cancer stem cell 
regulation, as well as breast tumor progression and metastasis. TAZ, a key component of the Hippo pathway, is highly 
expressed in triple negative breast cancer; however, the associations of genetic variations in this important pathway 
with breast cancer risk remain largely unexplored. Here, we analyzed 8309 germline variants in 15 genes from the Hippo 
pathway with a total of 3663 cases and 4687 controls from the African American Breast Cancer Epidemiology and Risk 
Consortium. Odds ratios (ORs) were estimated using logistic regression for overall breast cancer, by estrogen receptor 
(ER) status (1983 ER positive and 1098 ER negative), and for case-only analyses by ER status. The Hippo signaling pathway 
was significantly associated with ER-negative breast cancer (pathway level P = 0.02). Gene-based analyses revealed that 
CDH1 was responsible for the pathway association (P < 0.01), with rs4783673 in CDH1 statistically significant after gene-
level adjustment for multiple comparisons (P = 9.2 × 10−5, corrected P = 0.02). rs142697907 in PTPN14 was associated with 
ER-positive breast cancer and rs2456773 in CDK1 with ER-negativity in case-only analysis after gene-level correction for 
multiple comparisons (corrected P < 0.05). In conclusion, common genetic variations in the Hippo signaling pathway may 
contribute to both ER-negative and ER+ breast cancer risk in AA women.
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Introduction
Functional screens in Drosophila identified the Hippo signaling 
pathway, which regulates organ size by modulating cell growth, 
proliferation and apoptosis (1–3). The majority of the Hippo path-
way components are highly conserved from Drosophila to mam-
malian species, and dysregulation of this pathway is widely 
observed in cancer (4–6). The core of this pathway in mammals is 
composed of a kinase cascade wherein the STE20-like kinase 1/2 
(MST1/2), in complex with its regulatory protein salvador 1 (SAV1), 
phosphorylates and activates large tumor suppressor kinase 1/2 
(LATS1/2) in complex with its regulatory protein MOB kinase acti-
vator 1A (MOB1A). This in turn phosphorylates and inactivates 
the transcriptional co-activators, yes-associated protein (YAP)/
transcriptional coactivator with PDZ-binding motif (TAZ). When 
YAP/TAZ translocate to the nucleus, they induce expression of 
cell-proliferative and anti-apoptotic genes, mainly through inter-
actions with transcription factors, such as: TEA domain family 
members (TEADs) (3). In recent years, knowledge of the com-
plexity of YAP/TAZ regulation has expanded considerably. The 
G protein-coupled receptors (GPCRs) and the cytokine receptor 
leukemia inhibitory factor receptor (LIFR) are associated with 
the activation of LATS kinases (7,8). In addition, YAP/TAZ are also 
directly regulated by the extracellular matrix (9), mechanotrans-
duction (10,11), actin cytoskeleton and Rho GTPases (11,12).
We and others have previous shown that TAZ is overex-
pressed in breast cancers, especially in triple negative breast 
cancer (13–15). The expression levels and activity of TAZ are 
frequently upregulated in high-grade metastatic breast cancer 
(16–18). Activation of YAP induces epithelial to mesenchymal 
transition and promotes breast tumor metastasis (19,20). Both 
YAP and TAZ have been shown to be involved in breast cancer 
stem cell regulation (16,17,21,22) and mediated drug resistance 
in breast cancer (19,23). In addition, it has been demonstrated 
that hypermethylation of the promoter regions of LATS1/2 
occurred in breast cancers and the decreased expression of 
LATS1/2 was significantly associated with large tumor size and 
high lymph node metastasis (24).
Epidemiological studies indicate that African-American (AA) 
women are more likely to be diagnosed with more aggressive breast 
cancer, including estrogen receptor (ER)-negative and TN breast 
cancer, and have higher cancer mortality than European American 
(EA) women (25–27). Although the mechanisms underlying these 
disparities are largely unknown, emerging evidence supports that 
cancer biology may be different across patients of different ances-
tral background (25,28). Considering the critical role of Hippo signal-
ing pathway played in triple-negative breast cancer, we hypothesize 
that this pathway may contribute in part to the biological difference 
in breast cancer between AA and EA women. The African American 
Breast Cancer Epidemiology and Risk (AMBER) Consortium was estab-
lished to investigate potential genetic and non-genetic risk factors 
for aggressive breast cancer in AA women. Here, we comprehen-
sively examined genetic variations in Hippo signaling pathway 
with breast cancer risk in this large AA breast cancer consortium.
Study population and methods
The AMBER consortium is a large collaborative effort to 
aggregate an adequate sample size to study epidemiology of 
breast cancer subtypes in AA women. Established in 2011, the 
consortium consists of two case-control studies, the Women’s 
Circle of Health Study (WCHS) and the Carolina Breast Cancer 
Study (CBCS), and two prospective cohort studies, the Black 
Women’s Health Study (BWHS) and the Multiethnic Cohort 
(MEC). A  detailed description of the consortium and the four 
contributing studies can be found elsewhere (29–34).
The WCHS is a case-control study enrolling women aged 
25–75 with invasive breast cancer and ductal carcinoma in situ 
(DCIS), initially in New York City (NYC) and New Jersey (NJ), and 
later exclusively in NJ (31,32). Cases were ascertained in NYC 
hospitals with large referral patterns of AAs and through the 
NJ State Cancer Registry. Controls frequency matched on state, 
race and age were identified through random digital dialing and 
community events. The CBCS is a population-based case–con-
trol study in North Carolina beginning in 1993 (30). Breast cancer 
patients aged 20–74 were identified through the NC State Cancer 
Registry, and controls were enrolled through Division of Motor 
Vehicle lists and Health Care Finance Administration lists.
The BWHS is a prospective study of 59 000 AA women across 
the USA who were 21–69 years of age at the study entry in 1995 
and have been followed by biennial questionnaire since that 
time (33). Women diagnosed with breast cancer are identified 
by self-report in follow-up questionnaires, and confirmed by 
medical records, state cancer registries, and the National Death 
Index. The MEC is a multiethnic prospective cohort in Hawaii 
and southern California with follow-up of 215 000 men and 
women aged 45–75 at the time of study entry (1993–1996) (34). 
Breast cancer diagnoses identified through linkage to state can-
cer registries. Controls for the BWHS and MEC were AA partici-
pants who had not been diagnosed with breast cancer.
All study participants provided informed consent, and the 
study was approved by Institutional Review Boards at participat-
ing institutions. Estrogen receptor (ER) status information was 
obtained from pathology reports and/or Cancer Registry Data. 
The study population included in the genotype study has been 
previously described in detail (35). A brief summary of the num-
ber of cases and controls from each contributing study included 
in this analysis, with index age and ER status (for cases) is 
provided in Supplementary Table  1, available at Carcinogenesis 
Online.
Genetic marker selection, genotyping, quality control 
and imputation
Genes from select candidate pathways of interest were iden-
tified by querying the Molecular Signature Database (MSigDB) 
(36) and tagSNPs from each gene were chosen using criteria of 
r2 ≥ 0.8 and minor allele frequency ≥ 10% in the Yoruban (YRI) 
population from the 1000 Genome Project (37). These SNPs were 
added as part of the custom content to the Illumina Human 
Exome Beadchip v1.1 and samples from BWHS, CBCS and WCHS 
were genotyped by the Center for Inherited Disease Research 
(CIDR), followed by stringent sample and marker QC steps (38). 
Imputation to the 1000 Genomes data using the IMPUTE2 pro-
gram (39) was performed by the University of Washington (UW). 
MEC samples had been genotyped previously using the Illumina 
1M-Duo chip and also imputed to the 1000 Genomes data. The 
imputed MEC data were pooled with those from the BWHS, 
CBCS and WCHS to create a final analytical dataset. Markers 
with mismatching alleles or allele frequencies that were dif-
ferent by > 0.15 between MEC and the other three studies, and 
markers with MAF < 0.6% or imputation info score < 0.5 in either 
study were excluded. For the present analysis of the Hippo sign-
aling pathway, a total of 7017 variants in 14 genes belonging to 
this pathway were included (Table 2).
Abbreviations 
AA  African-American
ER  estrogen receptor
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Statistical analysis
To control for potential admixture bias, principal component 
analysis was conducted using the smartpca program in the 
EIGENSOFT package (40) to infer population structure. Paired 
sample relatedness was assessed by PLINK (41). As a result, 35 
individual outliers in principal component analysis and 162 
first-degree relatives identified were flagged for sensitivity 
analysis. No substantial changes in risk estimates were found 
after excluding these individuals and they were thus kept in 
the analysis. Ten PCs were tested for association with case–
control status while controlling for covariates, including index 
age, study, geographic region and DNA source. Although none 
was significantly associated with breast cancer risk, to be con-
servative, three PCs with a P < 0.10 were included in the logistic 
regression models.
In addition to analyzing overall breast cancer risk, stratified 
analyses were conducted by ER status compared to controls, as 
well as case-only analyses comparing ER− to ER+ cases. Three 
levels of analyses of genetic variations were performed: path-
way level, gene level and single marker level, under the hypoth-
esis that aggregating the effects of multiple markers within a 
gene or a biological pathway might be more statistically power-
ful and less prone to multiple testing bias than single marker 
analysis. Pathway- and gene-level analyses were performed 
first, using the adaptive rank truncated product (ARTP) statistic 
(42), which can optimize the number of single marker P values 
combined in each gene-level and pathway-level test. For path-
way-level analysis, the PIGE software implementation of the 
ARTP method takes gene-level information into consideration 
when combining markers in a pathway (https://cran.r-project.
org/web/packages/PIGE/index.html). To avoid redundancy of 
markers in high LD (r2 ≥ 0.8), the ARTP gene-level tests com-
bined the optimal number of most significant SNP P values 
from among the top 10 pruned-in SNPs for each gene. This 
number was deliberately chosen to ensure adequate represen-
tation of genetic variations in each gene, while not to include 
too many null variants to dilute the effects of truly causal mark-
ers. The ARTP pathway tests combined the optimal percentage 
(in 5% increments) of the most significant gene P values in each 
pathway, without exceeding 50%. This approach was chosen 
to ensure excellent representation of associated genetic vari-
ants, while not diluting any effects from truly causal markers 
by including too many null markers in the analysis. Following 
gene-level testing, single marker-level analyses were pursued 
using PLINK with dosage data and controlling for age, study, 
geographic region, DNA source and three top PCs. We corrected 
for multiple testing within these genes with a Bonferroni cor-
rection for the effective number of independent markers tested 
within a gene using Gao’s SimpleM approach (43), and called 
this the ‘gene-wide’ significance. Single marker associations for 
top genes were plotted with linkage disequilibrium data using 
the LocusZoom program (44).
Results
As shown in Table 1, the Hippo pathway was significantly associ-
ated with ER-negative breast cancer risk (pathway level P = 0.02), 
likely attributable to CDH1 (gene level P  =  0.004). When CDH1 
gene was removed from the analysis, the pathway-level signifi-
cance become non-significant (P = 0.63). The pathway was not 
associated with risk of overall cancer or ER-positive cancer, or 
with ER status in case-only analyses (pathway level P > 0.05). In 
analysis of genes and breast cancer risk, CDH1 was nominally 
associated with overall breast cancer risk (P = 0.02); and CDK1 
was nominally associated with ER negative disease in case-only 
analysis (P = 0.01).
Figure  1 displays the single variant associations of CDH1 
with ER-negative breast cancer risk. The best signal locus was 
an intronic SNP, rs4783673. The T allele was associated with 19% 
reduced risk of ER-negative breast cancer (OR = 0.81, 95% CI 0.73, 
0.90, P = 9.2E−5), which remained significant after correction for 
multiple testing at the gene level (corrected P = 0.02) (Table 2). 
When this SNP was removed, CDH1 remained significant at the 
gene level (P = 0.005) but the Hippo pathway was no longer sig-
nificant (P = 0.13). Although CDH1 was also associated with over-
all breast cancer risk at the gene level, no individual variants in 
the gene were significantly associated with overall breast cancer 
after correction for multiple testing (data not shown). The most 
significant SNP in CDH1 for overall breast cancer was rs4783673, 
the T allele of which was associated with a 12% reduced risk 
at a borderline significance level (OR = 0.88, 95% CI, 0.82, 0.94, 
P = 2E−4, corrected P = 0.06). This was the same variant identified 
above with ER-negative breast cancer, and thus the association 
with overall breast cancer risk was likely driven by this subtype.
No gene in the Hippo pathway was associated with 
ER-positive breast cancer at the gene level (Table  1). However, 
an intronic SNP rs142697907 in PTPN14 was significant at the 
single marker-level after within gene adjustment for multiple 
testing. The A allele was associated with a 75% increased risk of 
Table 1. P values of pathway- and gene-level test with breast cancer risk (P values lower than 0.05 is in bold) 
Gene # Total marker # Effective marker Overall ER+ ER− ER− versus ER+
Hippo pathway 7017 2244 0.36 0.83 0.02 0.24
AREG 666 186 0.45 0.89 0.29 0.41
CDH1 666 269 0.02 0.08 0.004 0.50
CDK1 195 74 0.73 0.65 0.09 0.01
CTGF 26 12 0.76 0.58 0.91 0.80
CTNNA1 939 149 0.72 0.99 0.97 0.96
CTNNB1 138 56 0.32 0.69 0.59 0.53
DLG5 714 166 0.63 0.64 0.64 0.75
FAT1 976 455 0.83 0.35 0.97 0.48
PTPN14 1151 384 0.29 0.21 0.09 0.20
RASSF1 53 32 0.76 0.57 0.99 0.41
SIAH1 10 7 0.35 0.22 0.14 0.21
STK4 586 113 0.96 0.96 0.79 0.22
TEAD4 430 188 0.27 0.52 0.41 0.69
WWTR1 467 153 0.73 0.33 0.54 0.07
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ER-positive cancer (OR = 1.75, 95% CI 1.33, 2.30, P = 7.4E−5, cor-
rected P = 0.03).
A 3′ UTR SNP, rs2456773 in CDK1 was likely the variant driving 
the association of CDK with ER status in case-only analysis. The 
C allele was associated with 25% increased odds of ER-negative 
versus ER-positive cancer (OR = 1.25, 95% CI 1.11, 1.42, P = 3.2E−4, 
corrected P = 0.02) (Table 2). A second nearby 3′ UTR SNP, rs10711 
in perfect LD with rs2456773 (r2 = 1.0), was also associated with 
ER status. In case-control analyses performed separately by ER 
status, rs2456773 was only associated with ER-negative cancer 
(OR = 1.20, 95% CI 1.06, 1.34, P = 0.003), but not with ER-positive 
cancer (OR = 0.96, 95% CI 0.88, 1.06, P = 0.42).
Discussion
Here, we report findings of a comprehensive analysis of germline 
variations in the Hippo signaling pathway with breast cancer 
risk and by tumor ER status. The unique strengths of the study 
include a large population of AA women with breast cancer and 
controls and a systematic interrogation of common genetic vari-
ations in all available genes in this pathway. We found evidence 
of the overall Hippo pathway being associated with ER-negative 
breast cancer risk, which may be attributed to CDH1. Our find-
ing corroborates that from laboratory studies linking the Hippo 
pathway with ER-negative and triple-negative breast cancer.
CDH1 encodes a classical member of the cadherin fam-
ily, which plays an important role in maintaining the epithe-
lial integrity. Down regulation of CDH1 has been considered as 
one of the main molecular alterations for tumor invasion and 
metastasis (45). Complete E-cadherin loss has been reported in 
86% to 100% of invasive lobular breast cancer (46). Interestingly, 
E-cadherin reduction has been found in triple negative breast 
cancer patients with lymph node metastasis (47,48). Given the 
well established role of somatic changes in CDH1 in cancer 
invasion and metastasis, a number of studies have investigated 
the associations of CDH1 germline variants with risk of vari-
ous human cancers. A  meta-analysis concluded that one SNP 
in the promoter region, rs16260 (-160 C>A), was associated with 
increased risk of all cancers, but not with breast cancer in strati-
fied analyses by cancer type (49). In our AA population, we did 
not find any association of rs16260 with breast cancer risk.
We also found a low frequency variant in PTPN14 associated 
with 75% increased risk of ER-positive breast cancer risk. PTPN14 
encodes a member of the protein tyrosine phosphatase, which 
has been shown to mediate the dephosphorylation of tyrosine 
residues in some adherens junction proteins such as β-catenin 
(50). In addition, it was reported that PTPN14 suppressed metas-
tasis by reducing the intracellular protein trafficking through 
the secretory pathway (51). We and other have previously dem-
onstrated that PTPN14 negatively regulated YAP oncogenic func-
tion through direct interaction with YAP (52) and activation of 
LATS1/2 proteins (53). Interestingly, PTPN14 loss-of-function 
and deleterious missense mutations were found in skin cancer 
(54). To our knowledge, there is no published study of germline 
variants in PTPN14 with cancer risk. It should be noted, however, 
that the variant we identified with ER-positive breast cancer had 
a low frequency of 0.02 and was imputed with a moderate info 
score of 0.83. Thus, the result should be interpreted with caution 
because of possible imputation inaccuracy. Nevertheless, given 
the growing research interest in PTPN14 in cancer, our data may 
provide support for further study of variants in this gene in 
breast cancer.
To explore whether the significant gene we identified in AA 
women were also associated with breast cancer in EA women, 
we queried all available variants in CDH1 using publicly avail-
able data from the GAME-ON GWAS look up tool. The T allele of 
rs4783673 in CDH1 was associated with slightly decreased risk of 
ER-negative breast cancer in an EA population (P = 0.07), which is 
consistent with our finding of this SNP in AA women. However, 
none of the variants in this gene was associated with overall or 
ER-negative breast cancer risk after correcting for multiple com-
parisons. The low replication rate of significant genetic variants 
from EA to AA populations and vice versa is not unexpected, as 
observed in previous studies from us and others (35,55,56). This 
low replication rate may be due to distinct differences in genetic 
architecture between the two populations.
Several limitations should be noted in our study. Although we 
included a large number of genes and variants in the analysis, 
Table 2. Top variants associated with breast cancer risk after gene-wide correction for multiple test (P ≤ 0.05)
SNP Gene A1/A2 Function A1 frequency Info score OR (95% CI) P Corrected P
ER-positive breast cancer
 rs142697907 PTPN14 A/G Intronic 0.02 0.83 1.75 (1.33–2.30) 7.42E−05 0.03
ER-negative breast cancer
 rs4783673 CDH1 T/C Intronic 0.65 0.99 0.81 (0.73–0.90) 9.21E−05 0.02
ER-negative versus ER-positive breast cancer
 rs2456773 CDK1 C/G 3′ UTR 0.25 0.98 1.25 (1.11–1.42) 3.22E−04 0.02
Figure 1. The single variant associations of CDH1 with ER-negative breast can-
cer risk. Plots of log-transformed P values from single marker analysis for top 
genes in each subgroup test were generated using the LocusZoom program. The 
labeled marker in the plots were the most significant SNP (index SNP) in each 
gene, and the LD between the each of other markers in the gene and the index 
SNP was color coded, with red color indicating strong LD (r2 > 0.8) and blue color 
indicating weak LD (r2 < 0.2). Genotyped SNPs were indicated by closed dots and 
imputed SNPs were indicated by closed squares. 
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several genes in the core Hippo signaling pathway, such as 
LAST1/2 and YAP1, were not included as candidates for tagSNP 
selection in development of the chip. Although SNPs in exonic 
regions of these genes were typed as the standard content in 
the exome chip array, variants in other regions of these genes 
were not typed. As a result, the marker density of these genes 
was much lower and was biased to exons, making imputed data 
from non-exonic regions more error-prone compared to genes 
selected as candidates in the genotyping process. Thus, we did 
not included Hippo pathway genes with only exonic SNPs typed 
in the analysis, and future studies with better coverage of the 
pathway are warranted. Another limitation of our study came 
from the lack of complete information on all immunohisto-
chemical markers needed to classify triple-negative or basal-
like breast cancer subtype. Given the emerging evidence from 
laboratory studies linking the Hippo pathway with triple nega-
tive breast cancer, it would be interesting to analyze genetic 
variants in this pathway with this subtype. In the AMBER con-
sortium, central staining and defining of breast cancer subtypes 
is ongoing, and follow up analysis will be conducted when such 
data become available. Lastly, the lack of functionality of the 
identified SNPs is a typical limitation of SNP association stud-
ies, including ours. However, the identified associations provide 
clues for future experimental studies to characterize the func-
tional impact of those genetic variations.
To conclude, in the first large study of common genetic vari-
ants in the Hippo signaling pathway with breast cancer risk in 
AA women, we found that this pathway was specifically associ-
ated with ER-negative breast cancer risk. Considering that AA 
women are at higher risk of ER-negative cancer than European 
American women, further studies are needed to assess whether 
the Hippo pathway may be a part of the biological differences 
underlying breast cancer disparities.
Supplementary material
Supplementary Table  1 can be found at http://carcin. 
oxfordjournals.org/
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